Medicines for Malaria Venture (MMV)

07/08/2025

Malaria is both a cause and consequence of poverty, slowing economic growth and trapping the individuals and families it infects in cycles of poverty. Yet, defeating by 2030 remains one of the highest-impact investments we can make in global health.

Let’s make it happen 📖 Learn how: bit.ly/4iluecm

06/08/2025

According to the Society for Family Health Nigeria, an NGO contributing to prevention efforts across the country, kills 9 people every hour in the country.

To address the severity of the situation, the NGO’s latest prevention campaign in the Kano State is taking an integrated approach, distributing 7.7 million insecticide-treated nets and over 15 million doses of seasonal malaria chemoprevention (SMC) medicines to children 5 and under.

To strengthen supply of antimalarial medicines and ensure access where they’re needed most, MMV has supported three African pharmaceutical manufacturers in obtaining WHO prequalification for preventive medicines used in SMC, including two in Nigeria.

Read about Society for Family Health’s campaign in the Guardian Nigeria: bit.ly/4l6w0iC

05/08/2025

📢 Calling all African scientists. Do you have an idea that can help accelerate drug discovery? The deadline for MMV’s 8th African call for proposals is fast approaching, but we’re still welcoming submissions in four priority areas:

🔬 Compounds with confirmed activity on any antimalarial lifecycle stage
🧪 Assay development and screening to support the discovery or development of novel antimalarials
👩‍💻 Computer-aided drug discovery
🧬 New innovative biology for malaria prevention and treatment

🗓️ Deadline: 29 August 2025
🔗 Apply now: bit.ly/4dLbSk7

04/08/2025

🦟 Effective vector surveillance is essential to control, but it requires deep understanding and practical skills.

Starting tomorrow, join the Asia Pacific Malaria Elimination Network (APMEN) and Malaria Consortium for a free online workshop led by Prof. Neil Lobo (University of Notre Dame), designed to support malaria programme managers and public health entomologists.

📅 Dates: 5–7 August
🔬 Register here: bit.ly/45fGEh5

Gain insights into tailoring vector control strategies, reducing human-vector contact and driving down transmission.

01/08/2025

🌏 At the 9th Asia Pacific Leaders’ Summit on Malaria Elimination, MMV and the APMEN Vivax Working Group convened national malaria leaders from Solomon Islands, South Korea, Pakistan and Nepal. The session focused on accelerating access to radical cure tools for relapsing Plasmodium vivax , with special emphasis on reaching remote and underserved populations.

📍 Hosted in Bali, this session built on discussions initiated at the 2024 APMEN Annual Meeting and reaffirmed the power of cross-country collaboration.

🔗 Read more: bit.ly/45mymVI

31/07/2025

On Pan-African Women’s Day ( ), MMV is celebrating the women dedicated to building a malaria-free future in Africa, the continent shouldering the majority of the disease burden.

Among them is Dr Monique Murindahabi, a global health expert leading the charge to bolster regional elimination efforts and break the cycles of poverty fuelled by the disease.

A malaria-free future for Africa can be powered by women — as scientists, leaders and changemakers.

30/07/2025

Brazil has achieved another milestone in the fight to eliminate .

The country has now integrated a child-friendly, single-dose radical cure for relapsing Plasmodium vivax malaria into its public health system—an important step towards protecting children from the most common form of the disease in Brazil and throughout Latin America.

Co-developed by MMV and GSK, tafenoquine (TQ):

✅ Was adopted into Brazil’s health system for use adults in 2023
✅ Was used to treat +4,000 adults in Brazil last year
✅ Will be available in a child-friendly, weight-based formulation that dissolves in water, making it easier to administer to children.

This development helps ensure more children complete treatment, which prevents relapses and disrupts the transmission cycle.

TQ is an invaluable addition to the antimalarial toolbox to protect both children and adults, and Brazil is blazing a trail that can inspire other countries to adopt this medicine to support their own elimination efforts and save more lives.

Learn more:

Child-friendly, dispersible tafenoquine formulation to help reduce relapses and break the disease transmission cycle in children.

30/07/2025

Malaria is surging in southern Africa.
New outbreaks have been reported in Zimbabwe, Botswana, Namibia and Eswatini. As Africa CDC warns, this resurgence underscores the urgent need for:

✅ Continued investment
✅ Regional cooperation
✅ Cross-border surveillance
✅ Timely and accurate data collection

We must not lose ground. Now is the time to double down on control efforts. Read more:

Malaria is on the rise in southern Africa, with several countries – including Botswana, eSwatini, Namibia and Zimbabwe – reporting new outbreaks, underscoring the ongoing challenges in eradicating the disease in Africa. Data from the Surveillance and Disease Intelligence Division of the Africa C...

29/07/2025

🎉 Congratulations to Timor-Leste!

The country has officially been certified malaria-free by the World Health Organization (WHO), and is now the third in the WHO South-East Asia region to achieve this incredible milestone. 🌍💪

From a peak of over 223,000 cases in 2006 to zero indigenous cases since 2021, this achievement reflects a tremendous public health effort.

With integrated case-based surveillance and a strong network of trained health workers, Timor-Leste has built a resilient system to keep malaria at bay and protect its communities.

👏 This is a big moment for the region and a reminder that elimination is possible. Read more: bit.ly/4miKa0Z

25/07/2025

🚨 Malaria in pregnancy puts both mother and baby at serious risk, yet treatment options – especially in the first trimester – remain limited.

That’s changing.

The SAFIRE consortium is an Africa-Europe partnership conducting a historic Phase 3 platform clinical trial to assess antimalarial medicines in early pregnancy. This collaboration will help expand treatment options for this long underrepresented group of patients.

🔗 Learn more: safire-consortium.org

24/07/2025

💻 In case you missed it: MMV researchers recently took part in a webinar hosted by Collaborative Drug Discovery to discuss breakthrough approaches to combating drug resistance and accelerating antimalarial development.

From next-generation medicines and the latest open science and AI initiatives, to strengthening R&D capacity in Africa, this conversation offers fresh insights into how we’re tackling drug resistance with our network of partners.

👉 Watch the full session here: bit.ly/46OSEII

23/07/2025

🦠 Drug resistance threatens decades of progress in the fight against .

A new review published in Clinical Microbiology and Infection underscores the urgent need to diversify the global antimalarial drug portfolio with novel interventions. This publication examines how MMV’s portfolio of promising non-artemisinin-based compounds currently in development is addressing this need.

Although attrition remains a possibility, researchers point to several promising candidate drugs with novel modes of action that could significantly enhance malaria treatment, address resistance and support malaria control and elimination efforts.

👉 Read the review: bit.ly/3GUJjVe